PROCEPT BioRobotics PRCT 深 滬
已收盤 07-18 16:00:00 美东时间
58.35
-0.580
-0.98%
華盛通- 最 高62.17
- 今 開59.68
- 成交量 183.42万股
- 最 低 58.19
- 昨 收 58.93
- 總市值 32.28亿
- 52周最高 103.8099
- 市盈率 靜 --
- 換手率 3.32%
- 52周最低 47.0401
- 委 比 91.47%
- 總股本 5532.87万
- 歷史最高 103.8099
- 量 比 2.02
- 振 幅 6.75%
- 歷史最低 15.38
- 每 手 1
- 風險率 13.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Morgan Stanley Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $68
Morgan Stanley analyst Patrick Wood maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $71 to $68.
07-15 21:11
Aquablation® Therapy’s Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule
PROCEPT BioRobotics announced that Aquablation therapy has been assigned a Category I CPT code (52XX1) effective January 1, 2026, replacing the existing Category III code 0421T. This milestone reflects the therapy's clinical value and adoption, offering durable symptom relief for BPH with minimal sexual side effects. The new code has a proposed Medicare payment rate of $540, slightly higher than TURP's $529. Aquablation, a robotic-assisted, ultra...
07-15 01:15
Oppenheimer Initiates Coverage On PROCEPT BioRobotics with Perform Rating
Oppenheimer analyst Suraj Kalia initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Perform rating.
07-07 21:52
PROCEPT BioRobotics to Present at Investor Conferences
PROCEPT BioRobotics ( ($PRCT) ) has provided an announcement. PROCEPT BioRoboti...
04-25 21:29
Procept beats Q1 estimates
Procept press release (NASDAQ:PRCT): Q1 GAAP EPS of -$0.45 beats by $0.04. Revenue of $69.2M (+55.5% Y/Y) beats by $3.8M. Full Year 2025 Financial Guidance The Company projects revenue for the full ye...
04-24 19:11
PROCEPT BioRobotics Raises FY2025 Sales Guidance from $320.00M to $323.00M vs $321.96M Est
PROCEPT BioRobotics (NASDAQ:PRCT) raises FY2025 sales outlook from $320.00 million to $323.00 million vs $321.96 million estimate.
04-24 19:09
美股大行评级 | 潜在涨幅223.78%！内克塔治疗获杰富瑞升目标价至2美元，上调至"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1117736711687032832.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 杰富瑞：上调内克塔治疗(NKTR)评级至"买入"，目标价从1美元升至2美元</p> <p>• Roth MKM：维持Lovesac Co.(LOVE)"买入"评级，目标价从22美元升至28美元</p> <p>• Macq
04-14 07:05
Procept Biorobotics Earnings Call Highlights Growth and Challenges
Procept Biorobotics Corp. (($PRCT)) has held its Q4 earnings call. Read on for ...
02-28 10:26
美股大行评级 | Stifel：维持Agilon Health"持有"评级，目标价从2美元升至3美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1101791398596456448.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Piper Sandler：维持Prothena Corp(PRTA)"超配"评级，目标价从94美元升至110美元</p> <p>• HC Wainwright & Co.：维持Karyopharm Therape
02-27 11:06
PROCEPT BioRobotics shares are trading higher after the company reported better-than-expected Q4 sales results.
PROCEPT BioRobotics shares are trading higher after the company reported better...
02-27 02:16
